Title page
Contents
ACKNOWLEDGEMENTS 4
1. INTRODUCTION 8
2. BACKGROUND 9
2.1. GLOBAL HEALTH EQUITY 9
2.2. CLINICAL TRIALS AND THE FIGHT AGAINST CANCER 11
3. REGULATORY FRAMEWORKS SUPPORTING GLOBAL COOPERATION AGAINST CANCER: CANCER MOONSHOT WITH A CASE STUDY ON PROJECT ORBIS AND CHINA 12
3.1. BENEFITS 15
3.2. OBSTACLES, SKEPTICISM, AND RESPONSES 17
4. BROADEN THE SCOPE: MORE COOPERATION APPROACHES AND CASES 19
4.1. MORE POLICY HARMONIZATION INITIATIVES: PROJECT PRAGMATICA AS AN EXAMPLE 19
4.2. MORE POTENTIAL ORBIS/PRAGMATICA PARTNERS: INDONESIA AS AN EXAMPLE 20
4.3. MORE FEASIBLE APPROACHES 20
5. CONCLUSION 22
REFERENCES 23
FIGURE 1. LIVES LOST TO CANCER VS. TO WARS 8
FIGURE 2. THE IMPACT OF INTERNATIONAL COLLABORATION AND INCREASING PATIENT ACCESS TO CLINICAL TRIALS TO SAVE LIVES 10
FIGURE 3. ESTIMATED AGE-STANDARDIZED CANCER INCIDENCE RATES (WORLD) 2020 11
FIGURE 4. NEW CANCER CASES OF CURRENT PROJECT ORBIS PARTNERS AND AS A PERCENTAGE OF CANCER INCIDENCE WORLDWIDE IN 2020 13
FIGURE 5. NUMBER OF APPROVALS IN PARTNERING COUNTRIES UNDER PROJECT ORBIS (2019-2023) 14
FIGURE 6. INCREASED COVERGE OF GLOBBAL CANCER CASES IN PROJECT ORBIS THROUGH CHINA'S PARTICIPATION 15
FIGURE 7. THE "5P"APPROACH: A COMPREHENSIVE STRATEGY OVERVIEW 21